Liquidia Reports Q2 2025 Net Loss of $41.6M, EPS of $0.49; Product Revenue Reaches $6.5M Following YUTREPIA FDA Approval
Liquidia Corporation reported a Q2 2025 net loss of $41.6 million, up from a $28.7 million loss in Q2 2024. Product revenue reached $6.5 million following FDA approval of YUTREPIA on May 23, 2025. R&D expenses decreased to $6.0 million, while SG&A expenses nearly doubled to $38.8 million. Total other expenses rose to $4.1 million. Cash and cash equivalents were $173.4 million as of June 30, 2025, down from $176.5 million at the end of 2024.
Liquidia Corporation has reported its financial results for the second quarter of 2025, revealing a net loss of $41.6 million, compared to a net loss of $28.7 million for the same period in 2024. The company’s product revenue, net, amounted to $6.5 million for the three-month period ending June 30, 2025, following the full FDA approval of YUTREPIA on May 23, 2025, and the commencement of its shipment to U.S. customers in June 2025. No product revenue was recognized in the corresponding period of the previous year. Research and development expenses decreased significantly to $6.0 million, down from $9.4 million in the previous year, primarily due to reduced personnel and YUTREPIA research and development expenses. However, selling, general, and administrative expenses nearly doubled to $38.8 million, driven by increased personnel costs, legal fees related to YUTREPIA litigation, and expenses supporting its commercialization. Total other expenses increased to $4.1 million from $1.5 million in the prior year, largely due to higher borrowings under the HCR Agreement. Cash and cash equivalents stood at $173.4 million as of June 30, 2025, slightly down from $176.5 million at the end of 2024. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9510536-en) on August 12, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
